ECE2013 Poster Presentations Thyroid cancer (64 abstracts)
Association acromegaly and thyroid cancer
Samia Achir , Fella Hasbellaoui , Anissa Khalifa & Mourad Semrouni
Department of Endocrinology and Nuclear Medicine, Algiers, Algeria.
Introduction: Acromegaly is a chronic disease caused by hypersecretion of GH and IGF1, it is associated with a high risk of cancer, however the excess incidence of thyroid cancer remains controversial, we report four cases.
Patients and methods: The diagnosis of acromegaly has been placed on a dosage of GH and IGFI, the diagnostic of carcinoma is based on histological study of the surgical specimen.
Results: The sex ♀ predominant (3/4). For three patients (no. 1, no. 2, no. 4) thyroid carcinoma was the mode of revelation of acromegaly. Thyroid hormone function was normal in three quarters of cases. It was a GMN or a united nodular. The FNA made in 50% of cases was contributive in 100%. Papillary form (3/4).
| Patient | Sex | Age | Goiter | TSH | FT4 | TCT | Cytopunction | Histological type | GH/IGF1 |
| No. 1 | ♀ | 34 | NTG | NLE | NLE | Nulle | Suspects | Papillary | >50 ng/l per NF |
| No. 2 | ♀ | 39 | GMN | NLE | NLE | NLE | – | vesicular | 0.42 mui/ml |
| 219 ng/l | |||||||||
| No. 3 | ♀ | 51 | GMN | BASSE | NLE | NLE | Suspects | Papillary microcarcinoma | 41. 3 mui/ml |
| 1168 ng/l | |||||||||
| No. 4 | ♂ | 40 | NT | NLE | NLE | NLE | – | Papillary | 9.5 mui/ml |
| 217 ng/l |
Conclusion: Despite the controversial results regarding the increased risk of thyroid cancer during the acromegaly, the exploring of thyroid is unavoidable and surgery must always be indicated when cytopuncture suspicious or malignant.
Volume 32
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more